Report cover image

Bullous Pemphigoid Market Report and Forecast 2024-2032

Publisher Expert Market Research
Published Feb 13, 2024
Length 180 Pages
SKU # EMAR18558308

Description

Bullous Pemphigoid Market Report and Forecast 2024-2032


Bullous Pemphigoid Market Report and Forecast 2024-2032

Bullous Pemphigoid Market Outlook

The bullous pemphigoid market size is anticipated to grow at a CAGR of 17.7% during the forecast period of 2024-2032, driven by development of novel therapies and rising incidence of geriatric population across major markets.

Bullous Pemphigoid: Introduction

Bullous Pemphigoid also known as scleroderma, is a rare chronic autoimmune disease characterized by the hardening and tightening of the skin and connective tissues. It affects not only the skin but also internal organs such as the heart, lungs, kidneys, and gastrointestinal tract, leading to various complications. Symptoms can include skin thickening, joint pain, digestive issues, and Raynaud's phenomenon. The exact cause of Bullous Pemphigoid is unknown, and treatment focuses on managing symptoms and preventing organ damage.

Key Trends in the Bullous Pemphigoid Market

There's a global trend towards the development of novel therapies targeting the underlying mechanisms of Bullous Pemphigoid. This includes research into immunosuppressants, biologics, and targeted therapies that aim to modulate the immune response and fibrotic processes characteristic of Bullous Pemphigoid. Clinical trials are exploring the efficacy of these new treatment approaches, offering hope for improved patient outcomes.

The market is seeing a shift towards personalized medicine, with treatments being tailored based on individual patient characteristics, disease subtypes, and severity. Biomarker research is gaining traction, aiming to identify patients who are more likely to respond to specific therapies. This approach seeks to optimize treatment effectiveness and reduce adverse effects.

There's an increasing emphasis on multidisciplinary care models to address the complex, multi-organ involvement in Bullous Pemphigoid. Specialized centers that offer comprehensive care involving rheumatologists, dermatologists, pulmonologists, and other specialists are becoming more common. These centers focus on holistic patient management, integrating pharmacological treatments with physical therapy, patient education, and psychological support.

Awareness campaigns and patient advocacy groups are playing a vital role in increasing public and healthcare professional awareness of Bullous Pemphigoid. These efforts are improving early diagnosis and access to care. Support networks provide valuable resources and emotional support for patients and their families, helping to navigate the challenges of living with Bullous Pemphigoid.

Given the rarity of Bullous Pemphigoid, many treatments fall under orphan drug status, benefiting from regulatory incentives designed to encourage the development of drugs for rare diseases. This support facilitates research and development activities, expedites the approval process, and ultimately brings innovative treatments to the market more quickly.

Bullous Pemphigoid Market Segmentation

Market by Treatment Type
  • Tablets
  • Capsules
  • Injectable
  • Other
Market Breakup by Diagnosis
  • Skin Biopsy
  • Physical Examination
  • Blood Test
Market Breakup by Drug Type
  • Immunosuppressant Medication
  • Steroids
  • Antibiotics & Antiseptics
  • Pain Relief Medication
Market Breakup by Route of Administration
  • Oral
  • Parenteral
  • Others
Market Breakup by End User
  • Hospitals
  • Specialty Clinics
  • Others
Market Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
Bullous Pemphigoid Market Overview

In North America, the Bullous Pemphigoid market is characterized by a strong focus on research and development of new treatments and a comprehensive approach to patient care. The region benefits from advanced healthcare infrastructure and a high level of awareness about autoimmune diseases. There's a significant emphasis on personalized medicine and the use of immunosuppressive drugs, alongside therapies targeting specific symptoms and organ involvement. Patient advocacy groups play a crucial role in supporting research and improving access to care.

Europe's market is driven by well-established healthcare systems and robust support for rare disease research, including Bullous Pemphigoid. Collaborative research efforts across European countries aim to understand the disease better and develop more effective treatments. The European Medicines Agency (EMA) provides regulatory pathways for orphan drugs, facilitating the development of new therapies. Integrated care models, combining pharmacological treatments with physical therapy and psychological support, are essential aspects of managing the condition.

In Japan, the Bullous Pemphigoid market benefits from a strong emphasis on healthcare innovation and a proactive approach to addressing rare diseases. The country has a well-developed healthcare system and policies supporting the development and approval of treatments for conditions like Bullous Pemphigoid. Japan's market is notable for its focus on early diagnosis and the use of cutting-edge technologies and therapies. Research and clinical trials in Japan often explore novel therapeutic approaches, including stem cell therapy and targeted molecular treatments.

Bullous Pemphigoid Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
  • Almirall
  • Pfizer Inc.
  • Greenstone LLC
  • F. Hoffmann-La Roche Ltd
  • SiriusLabs
  • Teva Pharmaceutical Industries Ltd
  • Astellas Pharma Inc.
  • Aegis Lifesciences Pvt. Ltd
  • Novartis AG
  • Mylan N.V.
  • Baxter
  • Bayer AG
  • Omega Laboratories
  • Merck KGaA.
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

*Please Note:* The report will take 7 business days to complete, after order confirmation.

Table of Contents

180 Pages
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Bullous Pemphigoid Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Bullous Pemphigoid Epidemiology Analysis – Seven Major Markets
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Bullous Pemphigoid Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Bullous Pemphigoid Epidemiology Forecast (2017-2032)
5.3.1 Germany Bullous Pemphigoid Epidemiology Forecast (2017-2032)
5.3.2 France Bullous Pemphigoid Epidemiology Forecast (2017-2032)
5.3.3 Italy Bullous Pemphigoid Epidemiology Forecast (2017-2032)
5.3.4 Spain Bullous Pemphigoid Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Bullous Pemphigoid Epidemiology Forecast (2017-2032)
5.4 Japan Bullous Pemphigoid Epidemiology Forecast (2017-2032)
6 Bullous Pemphigoid Market Overview – Seven Major Markets
6.1 Bullous Pemphigoid Market Historical Value (2017-2023)
6.2 Bullous Pemphigoid Market Forecast Value (2024-2032)
7 Bullous Pemphigoid Market Landscape – Seven Major Markets
7.1 Bullous Pemphigoid: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Bullous Pemphigoid Product Landscape
7.2.1 Analysis by Treatment Type
7.2.2 Analysis by Route of Administration
7.2.3 Analysis by End User
8 Bullous Pemphigoid Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Bullous Pemphigoid Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Bullous Pemphigoid Market Segmentation – Seven Major Markets
11.1 Bullous Pemphigoid Market by Treatment Type
11.1.1 Market Overview
11.1.2 Tablets
11.1.3 Capsules
11.1.4 Injectable
11.1.5 Other
11.2 Bullous Pemphigoid Market by Diagnosis
11.2.1 Market Overview
11.2.2 Skin Biopsy
11.2.3 Physical Examination
11.2.4 Blood Test
11.3 Bullous Pemphigoid Market by Drug Type
11.3.1 Market Overview
11.3.2 Immunosuppressant Medication
11.3.3 Steroids
11.3.4 Antibiotics & Antiseptics
11.3.5 Pain Relief Medication
11.4 Bullous Pemphigoid Market by Route of Administration
11.4.1 Market Overview
11.4.2 Oral
11.4.3 Parenteral
11.4.4 Others
11.5 Bullous Pemphigoid Market by End User
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Specialty Clinics
11.5.4 Others
11.6 Bullous Pemphigoid Market by Region
11.6.1 Market Overview
11.6.2 United States
11.6.3 EU-4 and the United Kingdom
11.6.3.1 Germany
11.6.3.2 France
11.6.3.3 Italy
11.6.3.4 Spain
11.6.3.5 United Kingdom
11.6.4 Japan
12 United States Bullous Pemphigoid Market
12.1 Bullous Pemphigoid Market Historical Value (2017-2023)
12.2 Bullous Pemphigoid Market Forecast Value (2024-2032)
12.3 Bullous Pemphigoid Market by Diagnosis Type
12.4 Bullous Pemphigoid Market by Treatment Type
13 EU-4 and United Kingdom Bullous Pemphigoid Market
13.1 Bullous Pemphigoid Market Historical Value (2017-2023)
13.2 Bullous Pemphigoid Market Forecast Value (2024-2032)
13.3 Germany Bullous Pemphigoid Market Overview
13.3.1 Bullous Pemphigoid Market by Diagnosis Type
13.3.2 Bullous Pemphigoid Market by Treatment Type
13.4 France Bullous Pemphigoid Market Overview
13.4.1 Bullous Pemphigoid Market by Diagnosis Type
13.4.2 Bullous Pemphigoid Market by Treatment Type
13.5 Italy Bullous Pemphigoid Market Overview
13.5.1 Bullous Pemphigoid Market by Diagnosis Type
13.5.2 Bullous Pemphigoid Market by Treatment Type
13.6 Spain Bullous Pemphigoid Market Overview
13.6.1 Bullous Pemphigoid Market by Diagnosis Type
13.6.2 Bullous Pemphigoid Market by Treatment Type
13.7 United Kingdom Bullous Pemphigoid Market Overview
13.7.1 Bullous Pemphigoid Market by Diagnosis Type
13.7.2 Bullous Pemphigoid Market by Treatment Type
14 Japan Bullous Pemphigoid Market
14.1 Bullous Pemphigoid Market Historical Value (2017-2023)
14.2 Bullous Pemphigoid Market Forecast Value (2024-2032)
14.3 Bullous Pemphigoid Market by Diagnosis Type
14.4 Bullous Pemphigoid Market by Treatment Type
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnerships and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Almirall
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Pfizer Inc.
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Greenstone LLC
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 F. Hoffmann-La Roche Ltd
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 SiriusLabs
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Teva Pharmaceutical Industries Ltd
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Astellas Pharma Inc.
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Aegis Lifesciences Pvt. Ltd
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Novartis AG
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Mylan N.V.
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Baxter
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Bayer AG
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Omega Laboratories
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
21.14 Merck KGaA.
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
22 Bullous Pemphigoid Market- Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us